Cytocast is actively seeking Pilot Study Partners to validate the effectiveness of our Cytocast Digital Twin™ technology. 

What is Cytocast Digital Twin™?  

Our high-performance computing platform models protein interactions within virtual cells, accurately predicting drug effects and potential side effects. This capability empowers informed decision-making at critical stages of drug development.

Key solutions our Cytocast Digital Twin platform is aimed to solve: 

• Early-Stage Candidate Testing: Cost-effective insights into potential side effects before committing to clinical trials. 
• Trial Risk Mitigation: Identifying candidates with higher failure risk due to side effects, and optimizing trial design. 
• Animal to Human Transition: Evaluating candidates for successful transition, reducing risks in human trials.  
• Pharma Acquisition Due Diligence: Thorough analysis of smaller company candidates for informed acquisitions. 

What do we offer?  

During the pilot study, we anticipate tackling some of the most pressing issues in drug development. Present us with a challenging task - whether you have a drug candidate that faced setbacks in a particular phase or a set of candidates with intriguing side effects or drug-drug interactions, Cytocast is here to provide you with valuable insights. 

Who We Are? 

Cytocast is a biotech startup driven by computational biology, bioinformatics, and high-performance computing experts. Join hands with us to reshape the future of healthcare. 

Get Involved! 

If you're a visionary pharma company, research institution, or healthcare professional eager to advance drug development, let's collaborate and redefine possibilities together! Reach out to collaboration@cytocast.com to explore this exciting opportunity for collaboration. 

Download our Onepager to learn more about Cytocast Digital Twin technology!